AIM ImmunoTech Inc. (AMEX:AIM) Q4 2022 Earnings Call Transcript

Page 3 of 3

Jason McCarthy: And durvalumab is approved, I think in – ovarian cancer too, is there a potential to expand that collaboration out there to ovarian?

Thomas Equels: Well, right now, our focus is on the work that we’ve done with pembrolizumab and I can’t really speak to future business opportunities, if we’re able to achieve success in pancreatic cancer with AstraZeneca’s drug durvalumab, it might open the opportunity to work with them in other indications. But we haven’t reached that point yet.

Jason McCarthy: Got it, thank you guys.

Thomas Equels: Well, thank you very much, Dr. McCarthy. We appreciate your interest and your coverage.

Operator: Thank you. Next question is coming from

Follow Aerosonic Corp (NYSEMKT:AIM)

Page 3 of 3